MedPath

Magnesium

Generic Name
Magnesium
Brand Names
Vitafol-one
Drug Type
Small Molecule
Chemical Formula
H2Mg
CAS Number
7439-95-4
Unique Ingredient Identifier
I38ZP9992A
Background

Magnesium is classified as an alkaline earth metal and has 2 hydration shells. The element can be found in abundance in the hydrosphere and in mineral salts such as dolomite and magnesium carbonate.

Common dietary sources of magnesium include nuts (cashews, peanuts, almonds), beans, bananas, apples, carrots, broccoli, and leafy greens. Magnesium is an important enzyme cofactor and is essential to several metabolic processes. Further, the mineral helps regulate blood pressure and is necessary for RNA, DNA and protein synthesis among several other functions.

Despite the importance of magnesium and its availability via several food sources, an estimated 56 to 68% of adults who live in developed, western countries do not meet the recommended daily intake (RDI) of magnesium. Several factors and common behaviours reduce the availability of magnesium in the diet such as food processing and cooking vegetables (which are normally a rich source of magnesium).

Indication

Healthy levels of magnesium can be achieved through a well balanced diet, but if food sources are insufficient, magnesium supplements can be used to prevent and treat magnesium deficiencies.

In medicine, various magnesium salts may be used in laxative and antacid products. For example, magnesium citrate is available over-the-counter and may be used to manage occasional constipation. Magnesium sulfate may be used on its own or with total parenteral nutrition to treat hypomagnesemia. Magnesium sulfate is also indicated to prevent seizures in pregnant women with pre-eclampsia, and to manage seizures associated with eclampsia.

Associated Conditions
Calcium Deficiency, Magnesium Deficiency, Zinc Deficiency
Clinical Trials
Related News

PROPHECI Trial Launches to Test Pyrophosphate Treatment for Rare Calcification Disorder PXE

A groundbreaking Phase II clinical trial has begun testing oral pyrophosphate (PPi) supplementation as a potential treatment for pseudoxanthoma elasticum (PXE), a rare genetic disorder causing abnormal calcification. The PROPHECI trial, conducted across two French centers, will evaluate whether PPi can reduce arterial calcification and improve outcomes in 99 PXE patients over 12 months.

FDA Approves Bizengri for NRG1 Fusion-Positive Lung and Pancreatic Cancers

• The FDA has granted accelerated approval to Bizengri (zenocutuzumab-zbco) for advanced pancreatic adenocarcinoma and non-small cell lung cancer with NRG1 gene fusions. • Bizengri is the first systemic therapy approved by the FDA specifically targeting NRG1 gene fusions in these cancers after prior systemic therapy. • Clinical trial data showed overall response rates of 40% in pancreatic cancer and 33% in NSCLC, with manageable side effects, supporting the approval. • This approval highlights the importance of biomarker testing to identify NRG1 fusions, enabling personalized treatment for these difficult-to-treat cancers.

Relaxed Potassium Control Non-Inferior to Tight Control for Preventing Atrial Fibrillation After CABG

• A recent study found that relaxed potassium control (supplementation only if levels drop below 3.6 mEq/L) is non-inferior to tight control (below 4.5 mEq/L) in preventing atrial fibrillation after CABG. • The TIGHT-K trial showed no significant difference in new-onset atrial fibrillation between the relaxed and tight potassium control groups post-CABG surgery. • Relaxed potassium control led to a four-fold reduction in costs related to potassium administration without increasing the risk of dysrhythmias or adverse clinical outcomes. • Findings suggest that routine high-normal potassium supplementation after CABG can be safely abandoned, improving patient experience and reducing healthcare costs.

Exploring Non-Opioid Options for Chronic Pain Management

• A review of studies highlights several non-opioid medications with potential benefits for chronic low back pain (CLBP), myofascial pain syndrome (MPS), and fibromyalgia (FM). • For CLBP, NSAIDs, antidepressants (duloxetine), and muscle relaxants (carisoprodol, cyclobenzaprine, diazepam) have demonstrated efficacy compared to placebo in some studies. • Pregabalin and duloxetine have shown superior pain relief compared to placebo for fibromyalgia, while lidocaine patches and BoNT-A injections may benefit myofascial pain syndrome. • Several studies suggest that combination therapies, such as nortriptyline/gabapentin and morphine/gabapentin, may offer enhanced pain relief and reduced side effects compared to monotherapy.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy